Leiomyosarcoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
Rekha (talk | contribs)
No edit summary
Rekha (talk | contribs)
No edit summary
Line 4: Line 4:


==Pathophysiology==
==Pathophysiology==
The pathogenesis of leimyosarcoma is characterized by malignant smoth muscle neoplasm that can appear in any site in the body but most commonly found in the uterus,small intestine and retro peritoneum.
The pathogenesis of leimyosarcoma is characterized by malignant smoth muscle neoplasm that can appear in any site in the body but most commonly found in the uterus,small intestine and retro peritoneum.<ref name="pmid20430913">Arnold LM, Burman SD, O-Yurvati AH (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20430913 Diagnosis and management of primary pulmonary leiomyosarcoma.] ''J Am Osteopath Assoc'' 110 (4):244-6. PMID: [https://pubmed.gov/20430913 20430913]</ref>


=== Gross Pathology ===
=== Gross Pathology ===

Revision as of 08:43, 14 June 2018

Leiomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leiomyosarcoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leiomyosarcoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leiomyosarcoma pathophysiology

CDC on Leiomyosarcoma pathophysiology

Leiomyosarcoma pathophysiology in the news

Blogs on Leiomyosarcoma pathophysiology

Directions to Hospitals Treating Leiomyosarcoma

Risk calculators and risk factors for Leiomyosarcoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pathophysiology

The pathogenesis of leimyosarcoma is characterized by malignant smoth muscle neoplasm that can appear in any site in the body but most commonly found in the uterus,small intestine and retro peritoneum.[1]

Gross Pathology

On gross pathology, leiomyosarcoma appears to be soft, large, yellow or tan solitary masses with fleshy cut surfaces and areas of hemorrhage and necrosis.

Microscopic Pathology

On microscopic histopathological analysis,prominent cellular atypia, abundant mitoses(15-30 per 10 high power field),and areas of coagulative necrosis are characteristic features of the leiomyosarcoma.Leiomyosarcoma of somatic soft tissue has a number of histologic subtypes including epithelioid leiomyosarcoma, myxoid leiomyosarcoma, inflammatory leiomyosarcoma, granular cell leiomyosarcoma and dedifferentiated leiomyosarcoma.4 The clinical importance of these subtypes has not been well studied.

Microscopic Pathology

{{#ev:youtube|6OkMCMXucqw}}

References

  1. Arnold LM, Burman SD, O-Yurvati AH (2010) Diagnosis and management of primary pulmonary leiomyosarcoma. J Am Osteopath Assoc 110 (4):244-6. PMID: 20430913


Template:WikiDoc Sources